10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The nightly ledger
Every 8-K, 10-Q and 10-K that AIR's companies filed on SEC EDGAR, and what each one changed in AIR's read. Material filings first, newest first — never ordered by price. For 8-K filing alerts, follow a company and turn on filing emails.
By event type: Acquisitions · Major contracts
Seven-day window, 2 weeks back · Material filings: 1629 · All filings: 1839
Wednesday 4 Nov473 filings read · 428 material
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
APA CorpAPA
8-K · Item 2.02 — Results of operations
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
MFA Financial reported Q3 2026 results with a GAAP net loss of $122.4M ($1.19/share) driven by Treasury yield spikes and spread widening. Distributable earnings of $0.26/share and economic book value decline of 10.6% reflect challenging mortgage market conditions.
The gap narrowed as the filings read less positively.
The price trend weakened.
8-KFiled 4 Nov 2026Banks
8-K · Item 2.02 — Results of operations
Q3 2026: ABTC grew Bitcoin holdings ~5% to ~8,427 BTC, increased Satoshis Per Share ~5% to ~11,572, achieved ~$126M net income and ~$221M Adjusted EBITDA despite seasonal power cost pressures. No share dilution via ATM or Bitcoin purchases.
AIR measured this for the first time; no change to report.
The price trend weakened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed as the filings read less positively.
The price trend weakened.
10-QFiled 4 Nov 2026All industries
Interparfums IncIPAR
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
8-KFiled 4 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $202.7M beat expectations with 7% sequential ARPU growth in Cancer Care Continuum. Company raised FY2026 revenue guidance mid-point and announced definitive agreement to sell Prenatal Health business to Labcorp for $210M, expected to improve profitability and growth rate.
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
TPC reported record Q3 2026 results: $1.7B revenue (+22% YoY), $125.4M operating income (+213% YoY), $0.39 EPS (+457% YoY). Raised full-year adjusted EPS guidance to $5.90–$6.10 from $5.15–$5.45. Backlog $20.4B; strong cash generation.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026Semiconductors
Applied Optoelectronics, Inc.AAOI
8-K · Items 1.01, 1.02, 2.03 — Material agreement
AAOI replaced its prior credit facility with a new $200M facility ($30M revolving, $170M term loan) maturing October 2030, with optional $50M incremental capacity. Paid $350K termination fee on prior facility.
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 4 Nov 2026Industrials
Adient plcADNT
8-K · Items 1.01, 3.03 — Material agreement
Adient's board approved a $400M increase in share repurchase authorization (total $1B) and adopted a Tax Benefits Preservation Plan to protect ~$3.5B in NOL carryforwards from Section 382 ownership-change limitations.
The filings read more positively.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026Industrials
Sunrun Inc.RUN
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
Sezzle Inc.SEZL
8-K · Item 2.02 — Results of operations
Sezzle reported Q3 2026 results with 42.6% YoY revenue growth to $166.5M, 79.3% net income growth to $47.8M, and 68.1% subscriber growth to 955K. Raised FY2026 guidance four times; now expects 42.5% revenue growth and $5.45–$5.50 adjusted EPS. Introduced FY2027 preliminary guidance of $7.20 adjusted EPS.
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
Natural Resource Partners LpNRP
8-K · Item 2.02 — Results of operations
NRP reported Q3 2026 results with $44.8M free cash flow, fully repaid $13.1M credit facility balance, and declared significantly increased distribution of $2.34/unit (vs. $0.75 prior quarter). Company nearing deleveraging completion despite challenging commodity markets.
More of the market is starting to notice.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026Software / SaaS
Toast, Inc.TOST
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026Banks
8-K · Item 2.02 — Results of operations
Chime reported Q3 2026 revenue of $718M (+32% YoY), achieved third consecutive quarter of GAAP profitability with $44M net income, and raised full-year 2026 guidance. Active Members grew 20% YoY to 10.9M with record 1.8M net additions over trailing 12 months.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Flywire CorpFLYW
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 earnings show NAV growth to $14.32/share (+40 bps QoQ), strong credit quality with no new non-accrual additions, $891M new commitments, and 10.3% annualized return on net income. Base dividend maintained at $0.31/share.
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
C. H. Robinson Worldwide, Inc.CHRW
8-K · Items 1.01, 2.03 — Material agreement
CHRW amended its credit agreement and note purchase agreement to extend maturity to 2031, increase revolving commitments to $1.25B, raise accordion facility to $625M, and add leverage holidays to accommodate the RXO acquisition.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026All industries
Stewart Information Services CorpSTC
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026All industries
Cass Information Systems IncCASS
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
8-KFiled 4 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Park-Ohio reported Q3 2026 record revenue of $459M (+15% YoY), gross margin expansion to 17.9%, and adjusted EPS of $1.04 (+60% YoY). Company raised FY2026 sales guidance to $1.75–$1.77B and adjusted EPS to $3.35–$3.50, citing strong demand across aerospace, AI data centers, and semiconductors.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026Semiconductors
Quarterly report (10-Q), period ending 26 Sep 2026
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 4 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 sales grew 11% YoY to $68.0mm with 12% organic growth. Gross margin improved 90bps (adjusted). Company raised FY2026 guidance to +11% sales and +18% adjusted EPS. Acquired B. Braun vascular assets for $19.2mm.
Market attention has faded.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026Biotech
Charles River Laboratories International, Inc.CRL
Quarterly report (10-Q), period ending 26 Sep 2026
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026Software / SaaS
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026Banks
8-K · Items 1.02, 2.02 — Material agreement terminated
Riot signed a 15-year, 910 MW triple-net powered land lease with a leading Frontier AI Lab at Corsicana for ~$28B total contract value (~$1.8B annual rent). Combined with prior contracts, Riot has now leased 1,151 MW representing ~$38B long-term revenue with expected $2B+ average annual NOI at full deployment.
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became cheaper on AIR's value read.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q2 FY2027 revenue grew 10% YoY to $49.9M; Recorded Music surged 18%. Net income doubled to $4.6M. Company raised full-year FY2027 revenue and Adjusted EBITDA guidance. Strategic catalog acquisitions completed.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026Industrials
8-K · Items 1.01, 2.03 — Material agreement
AeroVironment increased aggregate revolving credit commitments by $100M (from $350M to $450M) via Sixth Amendment to its credit agreement. Letter of credit sublimit raised to $150M. Facility matures October 2029, secured by substantially all company assets.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026Banks
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 26 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026Banks
NB Bancorp, Inc.NBBK
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026Biotech
Edgewise Therapeutics, Inc.EWTX
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The price trend strengthened.
8-KFiled 4 Nov 2026Biotech
Edgewise Therapeutics, Inc.EWTX
8-K · Item 2.02 — Results of operations
Edgewise reported Q3 2026 results featuring a $1.348B gain from sevasemten sale to Servier, positive Phase 2 EDG-7500 HCM data, Phase 3 initiation expected by year-end 2026, and first patient dosed in Phase 2 EDG-15400 HFpEF trial. Cash position strengthened to $1.74B.
More of the market is starting to notice.
The price trend strengthened.
10-QFiled 4 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026Industrials
Mayville Engineering Company, Inc.MEC
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 4 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q1 FY2027 net sales grew 6% to $386.8M, net income rose 11% to $29.5M, and diluted EPS increased 11% to $0.72. Company maintained full-year guidance of $1.55–$1.60B sales and $258–$268M adjusted EBITDA, citing strong Mineral Nutrition and Performance Products performance.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
MIDDLEBY CorpMIDD
8-K · Items 1.01, 2.03 — Material agreement
Middleby entered into a Ninth Amended and Restated Credit Agreement on November 4, 2026, refinancing its prior credit facilities with a $3.0 billion senior secured facility ($2.0B revolving, $1.0B term loan A) maturing November 4, 2031.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026Biotech
Ultragenyx Pharmaceutical Inc.RARE
Quarterly report (10-Q), period ending 30 Sep 2026
The filings read less positively.
The shares became dearer on AIR's value read.
The gap closed as the filings read less positively.
8-KFiled 4 Nov 2026Biotech
Viridian Therapeutics, Inc.\DEVRDN
8-K · Item 2.02 — Results of operations
Viridian reported Q3 2026 results with $24.7M Lumvoa revenue and 100+ patients on therapy, exceeding expectations. Pipeline advancing: elegrobart BLA submission Q1 2027, VRDN-292 phase 1 initiation Q4 2026. Cash position $955.2M supports path to profitability.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 4 Nov 2026Biotech
Rapport Therapeutics, Inc.RAPP
8-K · Item 2.02 — Results of operations
Rapport Therapeutics reported positive Phase 2 topline results for RAP-219 in bipolar mania, meeting primary and secondary endpoints with statistical significance. Lead candidate now has proof-of-concept in two indications. Company well-capitalized through end of 2029.
Progress is running ahead of attention.
8-KFiled 4 Nov 2026Biotech
Geron CorpGERN
8-K · Item 2.02 — Results of operations
Geron reported Q3 2026 net income of $1.4M vs. prior-year loss of $18.4M. RYTELO revenue grew 5% QoQ to $60.1M; demand up 10%. Company initiated European commercial launch with Germany availability expected by year-end. Lowered 2026 operating expense guidance.
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 results show modest same-restaurant sales growth (Applebee's +0.9%, IHOP +0.8%) but significant year-over-year declines in net income ($4.5M vs $7.0M), EPS ($0.37 vs $0.48), and nine-month adjusted free cash flow ($12.8M vs $68.2M). Operating cash flow declined 55% YTD.
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
American Financial Group IncAFG
8-K · Items 2.02, 8.01 — Results of operations
AFG reported Q3 2026 record core net operating earnings of $3.97 per share (48% YoY increase), record P&C pretax operating income of $406M, 9% premium growth, and declared a $3.50 special dividend ($290M aggregate). Annualized core operating ROE of 26%.
Progress is running ahead of attention.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Trinity Capital reported Q3 2026 results with record NII of $49.9M (up 34.9% YoY), 15.5% ROAE, NAV of $13.61/share, and $614.1M in funded investments. Maintained 28 consecutive quarters of consistent dividends at $0.51 for Q4.
Progress is running ahead of attention.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
Mcgrath RentcorpMGRC
8-K · Items 1.01, 2.03 — Material agreement
McGrath RentCorp issued $75M of 6.53% Series H Senior Notes due 2031 and amended its note purchase agreement, increasing the revolving shelf facility to $350M and raising cross-default thresholds from $10M to $20M.
The gap narrowed — attention is catching up.
8-KFiled 4 Nov 2026All industries
ARKO Corp.ARKO
8-K · Item 2.02 — Results of operations
Q3 2026 net income and Adjusted EBITDA exceeded prior year; full-year 2026 guidance raised to $156–157M. Strategic USPP acquisition announced (280M gallons, ~$30M annualized EBITDA accretion). Quarterly dividend of $0.50/share declared.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 results show 48% sales volume growth, 76% Adjusted EBITDA increase to $124M, net income of $49.3M, and $166M operating cash flow. Company declared $2.00/share special dividend, demonstrating strong cash generation from Blue Creek mine ramp-up ahead of schedule.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
Personalis, Inc.PSNL
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $25.6M (77% YoY growth) driven by clinical test volume surge to 13,157 (200% increase) and Medicare coverage expansion. Clinical revenue jumped to $4.4M from $0.4M. Cash position strong at $190.6M. Pending Tempus merger limits forward guidance.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026All industries
Trex Co IncTREX
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 4 Nov 2026All industries
Fortune Brands Innovations, Inc.FBIN
Quarterly report (10-Q), period ending 26 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 26 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Q3 2026: IBTROZI achieved $27.5M net product revenue (18% QoQ growth), established as ROS1 market leader. FDA approved sNDA with 49.7-month median duration of response. Safusidenib granted Fast Track Designation for IDH1-mutant glioma. Cash position $663.4M.
Market attention has faded.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
FC reported Q4 and FY2026 results within guidance. Enterprise North America invoiced amounts grew 4%, deferred revenue surged 17%, and Q4 Adjusted EBITDA increased 9%. FY2027 guidance projects revenue and EBITDA growth.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
HCI Group reported Q3 2026 pre-tax income of $116M (vs. $91M YoY) and diluted EPS of $6.45 (vs. $4.90 YoY). Nine-month pre-tax income reached $343M (vs. $285M YoY). Gross loss ratio improved to 20.7% from 22.0%. Premium growth of 5-7% driven by higher policy volume.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
OPKO agreed to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M cash plus up to $150M contingent consideration. Company also secured $125M additional royalty financing and advanced multiple clinical programs including Phase 1/2a dosing of OPK-8801001 for acromegaly.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 4 Nov 2026Industrials
Stanley Black & Decker, Inc.SWK
8-K · Item 2.02 — Results of operations
SWK reported Q3 2026 results with 4% organic growth, 760 bps gross margin expansion, and raised full-year 2026 EPS guidance significantly (113% GAAP growth at midpoint). Board approved $1B share repurchase authorization.
No notable change in AIR's read.
10-QFiled 4 Nov 2026All industries
Brinks CoBCO
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026Software / SaaS
Hubspot IncHUBS
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
BillionToOne reported Q3 2026 revenue of $123.0M (+47% YoY), with prenatal up 41% and oncology up 96%. Raised full-year 2026 guidance to $460–470M (+51–54% growth). Maintained GAAP profitability while launching new product.
Market attention has faded.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
10-QFiled 4 Nov 2026Biotech
Adaptive Biotechnologies CorpADPT
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026Software / SaaS
Red Violet, Inc.RDVT
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
The shares became cheaper on AIR's value read.
The price trend weakened.
10-QFiled 4 Nov 2026All industries
Innovex International, Inc.INVX
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
8-KFiled 4 Nov 2026Industrials
Vishay Precision Group, Inc.VPG
8-K · Item 2.02 — Results of operations
Q3 2026 adjusted EPS of $0.14 declined 53% YoY from $0.30. Adjusted operating margin fell to 4.9% from 6.9%. Currency headwinds ($3.4M) and gross margin compression offset 9.6% revenue growth. Nine-month adjusted EPS down 55% YoY.
Market attention has faded.
8-KFiled 4 Nov 2026Software / SaaS
Hubspot IncHUBS
8-K · Item 2.02 — Results of operations
HubSpot reported Q3 2026 revenue of $947.6M (+17% YoY), beating guidance. GAAP operating income surged to $71.9M from $11.2M; non-GAAP operating income grew 33% to $214.2M. Customer count reached 311,704 (+12%). Full-year guidance raised to $3.685–$3.687B revenue (+18% YoY).
Market attention has faded.
The price trend weakened.
10-QFiled 4 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
More of the market is starting to notice.
The shares became dearer on AIR's value read.
The price trend strengthened.
8-KFiled 4 Nov 2026Industrials
MATERION CorpMTRN
8-K · Item 2.02 — Results of operations
Materion reported record Q3 2026 results with net sales of $567.3M (+27.6% YoY), net income of $38.3M (+50.6% YoY), and adjusted EPS of $1.93 (+36.9% YoY). Company raised full-year adjusted EPS guidance to $7.10–$7.40 (+33% midpoint YoY). Record backlog and incoming orders up ~35% and ~25% YoY.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Industrials
Adient plcADNT
8-K · Item 2.02 — Results of operations
Q4 FY2026 net loss of $47M vs. $18M profit prior year. Full-year net loss of $17M vs. $281M loss prior year. Restructuring charges elevated at $74M (Q4) and $108M (FY). Adjusted EBITDA flat YoY at $884M, but margins compressed in Americas segment.
The filings read more positively.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
10-QFiled 4 Nov 2026All industries
NexPoint Residential Trust, Inc.NXRT
Quarterly report (10-Q), period ending 30 Sep 2026
The gap narrowed as the filings read less positively.
10-QFiled 4 Nov 2026All industries
ESAB CorpESAB
Quarterly report (10-Q), period ending 2 Oct 2026
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 4 Nov 2026All industries
ESAB CorpESAB
8-K · Item 2.02 — Results of operations
ESAB reported Q3 2026 record sales of $825M (+13.3% reported, +2.3% organic) but reduced full-year guidance. Core adjusted EBITDA forecast lowered to $603–607M from $615–625M; core adjusted EPS guidance cut to $5.28–$5.33 from $5.40–$5.50. Organic growth outlook reduced to 1.6–2.0% from 2.0–4.0%.
The gap narrowed — attention is catching up.
The price trend strengthened.
8-KFiled 4 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Relay reported Q3 2026 results with $849M cash runway into 2029. ReDiscover-2 breast cancer trial enrollment tracking ~1 year ahead of benchmarks, completing mid-2027. ASH presentation of vascular anomalies data scheduled December 2026. New TIE2 inhibitor program announced. First FDA approval of Relay-discovered molecule (lirafugratinib) achieved.
More of the market is starting to notice.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026Biotech
Quarterly report (10-Q), period ending 30 Sep 2026
The shares became dearer on AIR's value read.
8-KFiled 4 Nov 2026All industries
Quinstreet, IncQNST
8-K · Item 2.02 — Results of operations
QuinStreet reported record Q1 FY2027 results with revenue of $416.7M (+46% YoY), net income of $17.0M (+275% YoY), and adjusted EBITDA of $42.7M (+108% YoY). Company raised full-year FY2027 guidance for both revenue and adjusted EBITDA.
The reported numbers improved.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
8-KFiled 4 Nov 2026Industrials
8-K · Item 2.02 — Results of operations
Q3 2026 revenue of $24.9M (+25% YoY) exceeded expectations with record IDE revenue of $3.9M (+1,850% YoY). Company raised full-year 2026 revenue guidance to $92–93M (19–20% growth) and reduced cash burn 74% YoY to $2.4M.
Progress is running ahead of attention.
8-KFiled 4 Nov 2026Biotech
Acadia Pharmaceuticals IncACAD
8-K · Item 2.02 — Results of operations
Q3 2026 revenues of $342M (+22% YoY) exceeded expectations. DAYBUE sales surged 39% YoY to $140M; NUPLAZID grew 12% to $202M. Company raised full-year DAYBUE guidance to $505–$520M and narrowed total revenue range. Pipeline progress includes Phase 2 RADIANT data supporting Phase 3 development of remlifanserin in Alzheimer's disease psychosis.
No notable change in AIR's read.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
LandBridge reported Q3 2026 revenue of $70.9M (+39% YoY), net income of $34.0M (+68% YoY), and Adjusted EBITDA of $63.7M (+42% YoY). Company raised full-year 2026 Adjusted EBITDA guidance to $220–$235M. Completed ~25,000-acre acquisition and PowerBridge commenced data center construction.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
10-QFiled 4 Nov 2026Industrials
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
10-QFiled 4 Nov 2026All industries
Solstice Advanced Materials Inc.SOLS
Quarterly report (10-Q), period ending 30 Sep 2026
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Biotech
Mineralys Therapeutics, Inc.MLYS
8-K · Items 2.02, 5.02 — Results of operations
Mineralys reports Q3 2026 results with lorundrostat NDA under FDA review (PDUFA target December 22, 2026). New trial data shows 46% of resistant hypertension patients achieved blood pressure targets. Commercial launch preparations advancing with expanded sales force and patient support program.
Progress is running ahead of attention.
8-KFiled 4 Nov 2026All industries
8-K · Item 2.02 — Results of operations
Q3 2026 results show strong operational execution with $256M Adjusted EBITDA, $153M Adjusted Free Cash Flow, and $157M YTD shareholder returns. Birch acquisition on track for Q4 closing, expected to increase EBITDA 55% and free cash flow >100% pro forma.
No notable change in AIR's read.
8-KFiled 4 Nov 2026Banks
Hut 8 Corp.HUT
8-K · Item 2.02 — Results of operations
Hut 8 reported Q3 2026 results with full commercialization of Beacon Point AI data center campus, $26.6B in expected contract value, 1,300 MW capacity under exclusivity, $1.07B credit facility, and $250M shareholder returns via buybacks.
No notable change in AIR's read.
8-KFiled 4 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
Nuvectis achieved first global approval for ciprocopan (NXP100) in China for PNH in July 2026. Lead compound now in late-stage development with FDA discussions ongoing for U.S. market. Strong cash position of $140.7M extends runway to 2H 2029. NXP200 showed encouraging Phase 1b efficacy data.
Progress is running ahead of attention.
The price trend strengthened.
10-QFiled 4 Nov 2026All industries
Quarterly report (10-Q), period ending 30 Sep 2026
No notable change in AIR's read.
8-KFiled 4 Nov 2026Biotech
8-K · Item 2.02 — Results of operations
UroGen reported Q3 2026 revenue of $89.0M (vs. $27.5M YoY), driven by ZUSDURI's 35% QoQ growth to $68.0M. FDA accepted UGN-103 NDA with June 2027 PDUFA date. First UGN-501 patient dosed. Patent extended to July 2044.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026All industries
Dutch Bros Inc.BROS
8-K · Item 2.02 — Results of operations
Dutch Bros reported Q3 2026 revenue growth of 29.8% YoY to $549.8M, net income up 36.4% to $37.2M, and 14 consecutive quarters of positive same-shop sales. Raised 2026 guidance and announced accelerated 2027 shop opening target of 250 locations.
Market attention has faded.
The shares became cheaper on AIR's value read.
Progress is running ahead of attention.
The price trend weakened.
8-KFiled 4 Nov 2026Software / SaaS
8-K · Item 2.02 — Results of operations
Q3 2026 revenue grew 27.8% YoY to $292.9M with 28.3% operating margin. Net income margin expanded 600bps to 25.7%. Member growth accelerated to 46.7M (+30.7% YoY). FY2026 FCF guidance raised to $490M+. Board authorized $175M additional share repurchase.
More of the market is starting to notice.
The price trend strengthened.
Sun 22 Nov
CAPR · Capricor Therapeutics, Inc. · Regulatory date
As stated in the filing: “Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026 ●”
Announced by the company in 8-K on 10 Nov 2026
DYN · Dyne Therapeutics, Inc. · Regulatory date
As stated in the filing: “Capricor Therapeutics’ BLA for its cell therapy deramiocel is currently under FDA review with a PDUFA date of November 22, 2026.”
Announced by the company in 10-Q on 5 Nov 2026
SVRA · Savara Inc · Regulatory date
As stated in the filing: “The FDA determined that the Company’s responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026.”
Announced by the company in 10-Q on 9 Nov 2026
Fri 27 Nov
BBIO · BridgeBio Pharma, Inc. · Regulatory date
As stated in the filing: “The first participant was dosed in ASCEND-ATTR, the Phase 3b/4 study to prospectively test disease reversal with Attruby - BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review.”
Announced by the company in 8-K on 29 Oct 2026
Mon 30 Nov
COGT · Cogent Biosciences, Inc. · Regulatory date
As stated in the filing: “Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026 •”
Announced by the company in 8-K on 5 Nov 2026
JBIO · Jade Biosciences, Inc. · Regulatory date
As stated in the filing: “The FDA has also accepted a Biologics License Application for accelerated approval of povetacicept in IgAN, with a Prescription Drug User Fee Act target action date of November 30, 2026.”
Announced by the company in 10-Q on 13 Nov 2026
Wed 2 Dec
ARE · Alexandria Real Estate Equities, Inc. · Investor day
As stated in the filing: “We expect to introduce 2027 guidance and related assumptions at our Investor Day on December 2, 2026, consistent with our historical practice.”
Announced by the company in 8-K on 27 Apr 2026
Thu 3 Dec
EXEL · Exelixis, Inc. · Regulatory date
As stated in the filing: “In February 2026, we announced that the FDA had accepted our NDA and assigned a standard review, with a Prescription Drug User Fee Act (PDUFA) target action date of December 3, 2026.”
Announced by the company in 10-Q on 29 Oct 2026
Tue 8 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “In addition, the Company announced that both Global Automotive and Global Industrial will host separate investor days on December 8, 2026 and December 9, 2026, respectively.”
Announced by the company in 8-K on 9 Sep 2026
LGND · Ligand Pharmaceuticals Inc · Investor day
As stated in the filing: “Ligand will provide an updated 5-year outlook during the Company’s Investor Day on December 8, 2026.”
Announced by the company in 8-K on 14 Jul 2026
Wed 9 Dec
GPC · Genuine Parts Co · Investor day
As stated in the filing: “Investor Days GPC and Motion will host separate investor days in New York City, with GPC’s Investor Day scheduled for December 8, 2026, and Motion’s Investor Day scheduled for December 9, 2026.”
Announced by the company in 8-K on 9 Sep 2026
Sat 12 Dec
ANAB · Anaptysbio, Inc · Regulatory date
As stated in the filing: “FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP) GSK and Tesaro Litigation Update •”
Announced by the company in 8-K on 12 Nov 2026
Thu 17 Dec
CORT · Corcept Therapeutics Inc · Regulatory date
As stated in the filing: “Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026 “The ADA and EASD consensus statement is an important advance for the many patients whose difficult-to-control hyperglycemia is a manifestation of undiagnosed Cushing’s syndrome,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer.”
Announced by the company in 8-K on 3 Nov 2026
Mon 23 Nov
MATW · Matthews International Corp · All industries
Annual results due — last year filed 21 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 30%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 0
Tue 24 Nov
BLBD · Blue Bird Corp · Industrials
Annual results due — last year filed 24 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 30%, net income up 408%
AIR's current read: News flow Balanced, Gap Very high · 82
PFLT · PennantPark Floating Rate Capital Ltd. · All industries
Annual results due — last year filed 24 Nov 2025
AIR's current read: News flow Balanced, Gap Very high · 71
Wed 25 Nov
AMTM · Amentum Holdings, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 66%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 4
ARMK · Aramark · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2025, against a year earlier): revenue up 6%, net income up 23%
AIR's current read: News flow Balanced, Gap Medium · 10
CASH · Pathward Financial, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 3%, net income down 31%
AIR's current read: News flow Balanced, Gap Low · 0
CLSK · Cleanspark, Inc. · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue up 129%, net loss widened
AIR's current read: News flow Balanced, Gap Very high · 54
GAP · Gap Inc · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2024, against a year earlier): revenue down 7%, net income down 23%
AIR's current read: News flow Balanced, Gap Low · 3
ROAD · Construction Partners, Inc. · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 28%, net income up 35%
AIR's current read: News flow Balanced, Gap Low · 7
SJM · J M SMUCKER Co · All industries
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 7
SMG · Scotts Miracle-Gro Co · All industries
Annual results due — last year filed 25 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 1%, net income down 25%
AIR's current read: News flow Balanced, Gap Medium · 12
SMTC · Semtech Corp · Semiconductors
Quarterly results due — last year filed 25 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 16%, net income up 37%
AIR's current read: News flow Balanced, Gap Low · 0
TFSL · TFS Financial CORP · Banks
Annual results due — last year filed 25 Nov 2025
Last quarter (Q1 2019, against a year earlier): net income up 4%
AIR's current read: News flow Balanced, Gap Medium · 23
Fri 27 Nov
ATKR · Atkore Inc. · Industrials
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 8%, net income down 98%
AIR's current read: News flow Balanced, Gap Low · 0
BJ · BJ's Wholesale Club Holdings, Inc. · All industries
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q2 2027, against a year earlier): revenue up 16%, net income up 15%
AIR's current read: News flow Balanced, Gap Medium · 18
CENT · Central Garden & Pet Co · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 8%, net income down 5%
AIR's current read: News flow Balanced, Gap Low · 1
CFFN · Capitol Federal Financial, Inc. · Banks
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2020, against a year earlier): net income down 15%
AIR's current read: News flow Balanced, Gap Medium · 10
JJSF · J&J Snack Foods Corp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue down 6%, net income down 20%
AIR's current read: News flow Balanced, Gap Low · 0
PD · PagerDuty, Inc. · Software / SaaS
Quarterly results due — last year filed 26 Nov 2025
Last quarter (Q1 2027, against a year earlier): revenue up 1%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 0
SPH · Suburban Propane Partners Lp · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue unchanged, net loss widened
AIR's current read: News flow Balanced, Gap Medium · 21
UTI · Universal Technical Institute Inc · All industries
Annual results due — last year filed 26 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 7%, net income down 79%
AIR's current read: News flow Balanced, Gap Very high · 57
Mon 30 Nov
SNEX · StoneX Group Inc. · All industries
Annual results due — last year filed 28 Nov 2025
Last quarter (Q3 2026, against a year earlier): revenue up 15%, net income up 102%
AIR's current read: News flow Balanced, Gap Very high · 52
Tue 1 Dec
ESE · Esco Technologies Inc · Industrials
Annual results due — last year filed 1 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 14%, net income up 26%
AIR's current read: News flow Balanced, Gap Very high · 97
Wed 2 Dec
ASAN · Asana, Inc. · Software / SaaS
Quarterly results due — last year filed 2 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 10%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 0
UNFI · United Natural Foods Inc · All industries
Quarterly results due — last year filed 2 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
VSTS · Vestis Corp · All industries
Annual results due — last year filed 2 Dec 2025
Last quarter (Q3 2025, against a year earlier): revenue down 4%, net income turned to a loss
AIR's current read: News flow Balanced, Gap Low · 1
Thu 3 Dec
BOX · Box Inc · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 9%, net income up 43%
AIR's current read: News flow Balanced, Gap Low · 1
CRWD · CrowdStrike Holdings, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 26%, net income turned positive
AIR's current read: News flow Balanced, Gap Low · 5
HQY · Healthequity, Inc. · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 8%, net income up 10%
AIR's current read: News flow Balanced, Gap Low · 0
KSS · KOHLS Corp · All industries
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue down 5%, net income down 39%
AIR's current read: News flow Balanced, Gap Medium · 11
MEI · Methode Electronics Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
AIR's current read: News flow Balanced, Gap Low · 0
NCNO · nCino, Inc. · Software / SaaS
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 11%, net income up 145%
AIR's current read: News flow Balanced, Gap Low · 5
THO · Thor Industries Inc · Industrials
Quarterly results due — last year filed 3 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue down 8%, net income down 68%
AIR's current read: News flow Balanced, Gap Low · 4
Fri 4 Dec
AGX · Argan Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 62%, net income up 51%
AIR's current read: News flow Balanced, Gap Low · 9
AMBA · Ambarella Inc · Semiconductors
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 13%, net loss narrowed
AIR's current read: News flow Balanced, Gap Low · 7
BF-B · Brown Forman Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue down 1%, net income up 4%
AIR's current read: News flow Balanced, Gap Low · 0
CXM · Sprinklr, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 1%, net income down 44%
AIR's current read: News flow Balanced, Gap Low · 9
DCI · DONALDSON Co INC · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q4 2026, against a year earlier): revenue up 8%, net income up 13%
AIR's current read: News flow Balanced, Gap Low · 9
FIVE · Five Below, Inc · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2024, against a year earlier): revenue up 14%, net income down 10%
AIR's current read: News flow Balanced, Gap High · 27
GWRE · Guidewire Software, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 27%, net income down 64%
AIR's current read: News flow Balanced, Gap High · 44
NTNX · Nutanix, Inc. · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q3 2026, against a year earlier): revenue up 10%, net income up 14%
AIR's current read: News flow Balanced, Gap Medium · 22
REX · REX AMERICAN RESOURCES Corp · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue up 6%, net income up 336%
AIR's current read: News flow Balanced, Gap Low · 0
SAIC · Science Applications International Corp · Software / SaaS
Quarterly results due — last year filed 4 Dec 2025
AIR's current read: News flow Balanced, Gap High · 39
SWBI · Smith & Wesson Brands, Inc. · Industrials
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q1 2027, against a year earlier): revenue up 32%, net income turned positive
AIR's current read: News flow Balanced, Gap Very high · 87
TITN · Titan Machinery Inc. · All industries
Quarterly results due — last year filed 4 Dec 2025
Last quarter (Q2 2027, against a year earlier): revenue down 9%, net loss widened
AIR's current read: News flow Balanced, Gap Low · 0
Expected dates come from each company's filing history. They are not forecasts, and companies move them.
Sign in to follow companies
Follow a company and its filings show up here.
Sign inResearch, not tips. Filings come from SEC EDGAR; AIR's read is recomputed every trading day. A price move is shown as a fact beside a filing, never as the reason it is listed.